Side effects control in the chemotherapy with everolimus: single-center experience Original article
Article Sidebar
Main Article Content
Abstract
Background : Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of patients with RCC.
Purpose: We aimed to evaluate the frequency of severe adverse events during everolimus chemotherapy in patients with renal cell carcinoma.
Patients and methods: We analyzed data from medical records of patients with renal cell carcinoma treated with everolimus from January 2010 to February 2011. All patients had histologically confirmed renal cell carcinoma. Patients received everolimus in a single daily dose of 10 mg orally, in the 30-day cycles. The severity of adverse events were determined according to the scale of Common Toxicity Criteria for Adverse Events.
Results : In our database we identified 51 patients with renal cell carcinoma who underwent everolimus therapy. Median age was 57 years (95% CI: 55–66). The most common hematological severe adverse events were: anemia in 10% of the patients, and lymphopenia in 4% of the patients. There were no other hematological toxicities in the 3rd or 4th degree. Hand-foot syndrome occurred in 2% of the patients in the intensity of the third degree. Among severe metabolic complications most commonly observed adverse events were: hyperglycemia in 6% of the patients, hypercholesterolemia in 6% and hypertriglyceridemia in 4%. Dose reduction was required in 4% of the patients due to nonbacterial pneumonia.
Conclusions: In our study, everolimus was safe and well tolerated with few severe side effects.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Pham P.T., Pham P.C., Danowitch G.M. et al.: Sirolimus associated pulmonary toxicity. Transplantation 2004; 77: 1215-1220.
3. Wysocki P.J.: mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 2009; 9(3): 231-241.
4. Sedrani R. et al.: Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant. Proc. 1998; 30: 2192-2194.
5. Lane H.A. et al.: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 2009; 15: 1612-1622.
6. Common Terminology Criteria for Adverse Events, Version 3,0, revised June 10, 2003. National Cancer Institute. Online: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
7. Charakterystyka produktu leczniczego. Online: http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_Product_Information/human/001038/WC500022814.pdf.
8. Motzer R.J. et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo controlled phase III trial. Lancet 2008; 372: 449-456.
9. Motzer R.J. et al.: Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors. Cancer 2010; 116: 4256-65.
10. Figlin R.A. et al.: Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. J. Clin. Oncol. 2011; 29: (suppl. 7; abstr. 304).
11. White D.A., Camus P., Endo M. et al.: Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. Am. J. Respir. Crit. Care Med. 2010; 182: 396-403.
12. Pham P.T., Pham P.C., Danowitch G.M. et al.: Sirolimus associated pulmonary toxicity. Transplantation 2004; 77: 1215-1220.
13. Wysocki P.J.: mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 2009; 9(3): 231-241.
14. Huffman T.A., Monthe-Satney I., Lawrence J.C. Jr.: Insulin-stimulated phosphorylation of lipid mediated by the mammalian target of rapamycin. Proc. Natl. Acad. Sci. USA 2002; 99: 1047-1052.